These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29121264)

  • 1. Persistent CNS toxicity in a patient receiving posaconazole tablets after discontinuation of voriconazole due to supratherapeutic serum levels.
    Foolad F; Kontoyiannis DP
    J Antimicrob Chemother; 2018 Jan; 73(1):256-258. PubMed ID: 29121264
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
    Tang L; Yang XF; Qiao M; Zhang L; Tang XW; Qiu HY; Wu DP; Sun AN
    J Mycol Med; 2018 Jun; 28(2):379-383. PubMed ID: 29673771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole-associated severe hyponatremia.
    Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
    Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation.
    Pettit NN; Miceli MH; Rivera CG; Narayanan PP; Perissinotti AJ; Hsu M; Delacruz J; Gedrimaite Z; Han Z; Steinbeck J; Pisano J; Seo SK; Paskovaty A
    J Antimicrob Chemother; 2017 Aug; 72(8):2355-2358. PubMed ID: 28475803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
    Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
    Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of obesity on voriconazole serum concentrations.
    Koselke E; Kraft S; Smith J; Nagel J
    J Antimicrob Chemother; 2012 Dec; 67(12):2957-62. PubMed ID: 22915462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent photopsia following course of oral voriconazole.
    Kadikoy H; Barkmeier A; Peck B; Carvounis PE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):387-8. PubMed ID: 20653481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis.
    Conant MM; Sha BE; Proia LA
    Mycoses; 2015 May; 58(5):313-4. PubMed ID: 25728539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
    Chishimba L; Niven RM; Cooley J; Denning DW
    J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles.
    Thompson GR; Bays D; Cohen SH; Pappagianis D
    Antimicrob Agents Chemother; 2012 Jan; 56(1):563-4. PubMed ID: 22005993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
    Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
    Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough invasive fungal infection under the use of posaconazole and voriconazole.
    Lee SH; Sun HY; Ko BS; Chang SC
    J Formos Med Assoc; 2016 May; 115(5):384-5. PubMed ID: 25891760
    [No Abstract]   [Full Text] [Related]  

  • 14. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
    Chau MM; Kong DC; van Hal SJ; Urbancic K; Trubiano JA; Cassumbhoy M; Wilkes J; Cooper CM; Roberts JA; Marriott DJ; Worth LJ
    Intern Med J; 2014 Dec; 44(12b):1364-88. PubMed ID: 25482746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.
    Andes D; Lepak A
    Clin Infect Dis; 2012 Aug; 55(3):391-3. PubMed ID: 22610924
    [No Abstract]   [Full Text] [Related]  

  • 18. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
    Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
    Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.